IRCT20191209045671N3
Recruiting
Phase 3
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function tests in type 2 diabetic patients with non-alcoholic fatty liver, a clinical trial study
Semnan University of Medical Sciences0 sites60 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Semnan University of Medical Sciences
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All type 2 diabetic patients with non\-alcoholic fatty liver
- •Having the consent to participate in the study
- •Age between 20 to 65 years
- •Healthy physical status
Exclusion Criteria
- •history of taking SGLT2 inhibitors
- •being pregnant for women
- •history of malignancy and diseases such as AIDS and hepatitis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
Recruiting
Phase 4
The effect of empagliflozin in patients with idiopathic edemaIdiopathic edema.Edema, unspecifiedR60.9IRCT20230314057712N1Ahvaz University of Medical Sciences70
Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90